fbpx

Human Progress Logo Human Progress

01 / 05
New Data on Remarkable Malaria Vaccine Impact

Gavi | Vaccination

New Data on Remarkable Malaria Vaccine Impact

“One year since the launch of routine malaria vaccinations in Africa, over 9.8 million doses of malaria vaccines (in total 12 million since 2023) have been delivered to 17 endemic countries through the Gavi malaria vaccination programme.

Surpassing the initial target of 15 countries, the pace of rollout is an indication of the high demand for this new tool as well as years of preparation by countries and partners. In total, an estimated 5 million children in these 17 countries that collectively represent more than 70% of the world’s malaria burden have been protected…

Data released this month by Cameroon’s Expanded Programme on Immunisation (EPI) found that districts included in the first wave of vaccination saw a higher drop, of 17% in all-cause hospital/clinic consultations for children under five years than those areas without the vaccine. About 60% of the malaria-vaccinating districts recorded a drop in all-cause under-five deaths, and 57% recorded a drop in deaths linked to malaria in children aged under five.

With the vaccine administered so far to over 130,000 children in the country, experts caution that – while these results are promising and consistent with MVIP findings – additional data, study and follow-ups are needed to demonstrate the direct impact of the vaccine.”

From Gavi.

Medical Xpress | Vaccination

mRNA-1010 Superior to Standard-Dose Vaccine for Preventing Flu

“For adults aged 50 years or older, an investigational messenger RNA (mRNA)-based vaccine (mRNA-1010) is superior to standard-dose licensed vaccines for preventing influenza-like illness, according to a study published in the New England Journal of Medicine…

Overall, 20,350 participants received mRNA-1010 and 20,353 received the standard-dose comparator. The researchers found that 2.0% and 2.8% of the recipients of mRNA-1010 and the standard-dose comparator, respectively, had RT-PCR-confirmed, protocol-defined influenza-like illness, corresponding to a relative vaccine efficacy of 26.6% and meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions occurred more often with mRNA-1010 than the standard-dose comparator; they were mainly mild-to-moderate and transient. Overall, 2.2% and 1.9% of recipients of mRNA-1010 and the standard-dose comparator, respectively, had serious adverse events.”

From Medical Xpress.

Gavi | Vaccination

Burkina Faso Celebrates Malaria Vaccine Impact

“Authorities report an unprecedented decline in malaria rates at the national level. At a press briefing in February 2026, Health Minister Robert Kargougou said the total number of recorded malaria cases fell from 10,805,020 in 2024, to 7,329,278 in 2025, a decrease of 32%. Over the same period, deaths fell from 3,523 to 1,979, a drop of 44%. Among children under five, cases declined by 39%, while mortality fell by more than 40%.”

From Gavi.

NBC News | Vaccination

Pancreatic Cancer nRNA Vaccine Shows Lasting Results

“Balachandran and his team published the results of the Phase 1 clinical trial last year. At the time, the patients, all of whom had early-stage disease before they joined the trial, had only been tracked for just over three years, and it was unclear whether the immune response would last and lead to the patients living longer, he said. New data collected during the trial’s six-year follow-up period shows that it may. Those findings will be presented Monday at the American Association for Cancer Research’s annual meeting in San Diego.

Six years after treatment, Gustafson and six others who responded to the treatment are still alive, along with two of the eight people who did not respond. Two of the responders, including the one who died, had a cancer recurrence; Gustafson’s cancer has not come back.”

From NBC News.

World Health Organization | Vaccination

Nearly 20 Million Saved in Africa Through Measles Vaccinations

“Nearly 20 million measles-related deaths have been averted in Africa since 2000 thanks to increasing vaccination coverage, according to the first-ever detailed analysis of immunization targets on the continent. 

The analysis, by World Health Organization (WHO) in the African region, and Gavi, the Vaccine Alliance, also found that alongside the 19.5 million measles deaths averted, more than 500 million children in Africa have been protected through routine immunization between 2000 and 2024.”

From World Health Organization.